CIAM
BCAX

Caitong International Asset Management’s Bicara Therapeutics BCAX Stock Holding History

Caitong International Asset Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.6K Sell
2,544
-3,231
-56% -$55.6K 0.01% 786
2025
Q4 		$97.2K Buy
5,775
+4,585
+385% +$78.3K 0.02% 437
2025
Q3 		$18.8K Buy
+1,190
New +$13.3K 0.01% 735
2025
Q1 		– Sell
-76
Closed -$1.32K – 2584
2024
Q4 		$1.32K Buy
+76
New +$1.58K ﹤0.01% 1269

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Caitong International Asset Management's BCAX Position: Q1 2026 in Review

Caitong International Asset Management reduced its Bicara Therapeutics (BCAX) stake by 56% in Q1 2026, selling an estimated $55.6K and leaving 2,544 shares worth $50.6K. The position accounts for 0.01% of the portfolio, ranked #786.

Caitong International Asset Management first reported a position in BCAX in Q4 2024 and has held it in 4 quarters since. The position peaked at $97.2K in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Caitong International Asset Management held 2,544 shares of Bicara Therapeutics worth $50.6K as of Q1 2026.
  • Caitong International Asset Management sold 3,231 Bicara Therapeutics shares in Q1 2026, an estimated $55.6K.
  • Bicara Therapeutics made up 0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #786 holding.
  • Caitong International Asset Management first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Caitong International Asset Management's Bicara Therapeutics position peaked at $97.2K in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.